TEMPUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Tempus AI, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Tempus AI, Inc. following a class action complaint that alleges breaches of fiduciary duties by the company's board of directors during the specified class period [1][2]. Group 1: Allegations and Issues - The complaint alleges that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2]. - Concerns were raised regarding the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2]. - The business model of Tempus-acquired Ambry is criticized for aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2]. - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2]. - These issues collectively indicate weaknesses in Tempus' core operations and revenue prospects [2]. Group 2: Financial Impact - Following the release of a report by Spruce Point Capital Management that raised significant concerns about Tempus' management and financial reporting, the stock price of Tempus fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 on May 28, 2025 [3][4]. Group 3: Legal and Contact Information - Long-term stockholders of Tempus are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and potential claims [1][5]. - The law firm specializes in representing individual and institutional investors in complex litigation across various courts [6].